DE60333387D1 - Triazolopyridazine als proteinkinase-inhibitoren - Google Patents

Triazolopyridazine als proteinkinase-inhibitoren

Info

Publication number
DE60333387D1
DE60333387D1 DE60333387T DE60333387T DE60333387D1 DE 60333387 D1 DE60333387 D1 DE 60333387D1 DE 60333387 T DE60333387 T DE 60333387T DE 60333387 T DE60333387 T DE 60333387T DE 60333387 D1 DE60333387 D1 DE 60333387D1
Authority
DE
Germany
Prior art keywords
protein kinase
triazolopyridazine
kinase inhibitors
compounds
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60333387T
Other languages
English (en)
Inventor
Jeremy Green
Ronald Grey Jr
Albert C Pierce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60333387D1 publication Critical patent/DE60333387D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/503Pyridazines; Hydrogenated pyridazines spiro-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
DE60333387T 2002-12-18 2003-12-17 Triazolopyridazine als proteinkinase-inhibitoren Expired - Lifetime DE60333387D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43512402P 2002-12-18 2002-12-18
PCT/US2003/039990 WO2004058769A2 (en) 2002-12-18 2003-12-17 Triazolopyridazines as protein kinases inhibitors

Publications (1)

Publication Number Publication Date
DE60333387D1 true DE60333387D1 (de) 2010-08-26

Family

ID=32682164

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60333387T Expired - Lifetime DE60333387D1 (de) 2002-12-18 2003-12-17 Triazolopyridazine als proteinkinase-inhibitoren

Country Status (15)

Country Link
US (1) US7268136B2 (de)
EP (1) EP1575959B1 (de)
JP (1) JP4817661B2 (de)
KR (1) KR101075812B1 (de)
CN (1) CN100567296C (de)
AT (1) ATE473980T1 (de)
AU (1) AU2003297161B8 (de)
CA (1) CA2510534C (de)
DE (1) DE60333387D1 (de)
HK (1) HK1087700A1 (de)
MX (1) MXPA05006478A (de)
NO (1) NO20053470L (de)
NZ (1) NZ541151A (de)
RU (1) RU2005122484A (de)
WO (1) WO2004058769A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040171062A1 (en) * 2002-02-28 2004-09-02 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
CA2503905A1 (en) * 2002-09-16 2004-03-25 Plexxikon, Inc. Crystal structure of pim-1 kinase
CN100567502C (zh) * 2003-04-03 2009-12-09 株式会社康福来 药学制剂
FR2876584B1 (fr) * 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de la kenpaullone pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US8053454B2 (en) 2005-10-06 2011-11-08 Exelixis, Inc. Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3
BRPI0620292B1 (pt) 2005-12-21 2021-08-24 Janssen Pharmaceutica N. V. Compostos de triazolopiridazinas como moduladores da cinase, composição, uso, combinação e processo de preparo do referido composto
JP2009538899A (ja) * 2006-05-30 2009-11-12 ファイザー・プロダクツ・インク トリアゾロピリダジン誘導体
JP2010500365A (ja) 2006-08-07 2010-01-07 インサイト・コーポレイション キナーゼ阻害剤としてのトリアゾロトリアジン
EP2066676A1 (de) * 2006-09-18 2009-06-10 Vertex Pharmaceuticals, Inc. Heterozyklische hemmer von c-met und anwendungen davon
ES2393130T3 (es) * 2006-10-23 2012-12-18 Sgx Pharmaceuticals, Inc. Triazoles bicíclicos como moduladores de proteínas quinasas
SG176461A1 (en) * 2006-11-06 2011-12-29 Supergen Inc Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
AU2007323725B2 (en) 2006-11-22 2014-02-20 Incyte Holdings Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
MX2009011578A (es) 2007-04-25 2009-11-11 Exelixis Inc 6-fenilpirimidinonas como moduladores de pim.
US8188083B2 (en) * 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
KR20090031122A (ko) * 2007-09-21 2009-03-25 주식회사 중외제약 인다졸 골격을 함유하는 화합물, 이의 제조방법 및 상기화합물을 함유하는 약제학적 조성물
CN101878219B (zh) 2007-09-27 2014-04-02 西班牙国家癌症研究中心 用于作为蛋白激酶抑制剂使用的咪唑并噻二唑类
NZ602791A (en) 2008-05-21 2014-04-30 Incyte Corp Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
US8895550B2 (en) 2008-08-19 2014-11-25 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
US8987251B2 (en) 2008-08-19 2015-03-24 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
US8557809B2 (en) 2008-08-19 2013-10-15 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為pim激酶抑制劑之三唑吡啶化合物
FR2940284B1 (fr) * 2008-12-19 2011-02-18 Sanofi Aventis Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
JP2012517971A (ja) * 2009-02-13 2012-08-09 フォーヴィア・ファーマシューティカルズ キナーゼ阻害薬としての[1,2,4]トリアゾロ[1,5−a]ピリジン類
EP2414369B1 (de) 2009-04-02 2015-08-12 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Imidazo[2,1-b][1,3,4]thiadiazole derivative
CN102791715B (zh) 2009-12-31 2016-04-27 卡洛斯三世国家癌症研究中心基金会 用作激酶抑制剂的三环化合物
EA025304B1 (ru) 2010-02-03 2016-12-30 Инсайт Холдингс Корпорейшн ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012098387A1 (en) * 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
ME02365B (de) 2011-02-25 2016-06-20 Array Biopharma Inc Triazolopyridinverbindungen als pim-kinase-hemmer
WO2012125667A1 (en) * 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
MX2013012661A (es) 2011-04-29 2014-03-27 Amgen Inc Compuestos de piridazina biciclicos como inhibidores pim.
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2013001310A1 (en) * 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
WO2013004984A1 (en) * 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
WO2013013188A1 (en) 2011-07-21 2013-01-24 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
AU2012314501B2 (en) * 2011-09-27 2017-02-16 Genfit Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists
US9187484B2 (en) * 2012-05-02 2015-11-17 Southern Research Institute Triazolopyridazine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
EP2864336B1 (de) 2012-06-06 2016-11-23 Constellation Pharmaceuticals, Inc. Benzo[b]isoxazolazepinbromdomänenhemmer und verwendungen davon
CN102938491B (zh) * 2012-09-28 2014-12-10 华为终端有限公司 天线、组合天线和移动终端
WO2014134583A2 (en) * 2013-02-28 2014-09-04 Washington University Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors
GB201321745D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
EP3157928B1 (de) 2014-06-20 2019-02-13 Constellation Pharmaceuticals, Inc. Kristalline formen von 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamid
CN109651253B (zh) * 2017-10-12 2022-03-25 上海医药工业研究院 苯丙烯酸酯衍生物及其作为神经保护药物的应用
CN108498512A (zh) * 2018-04-22 2018-09-07 于志国 一种治疗心力衰竭的药物组合物及其制备方法和用途
CN109045036B (zh) * 2018-07-19 2020-10-02 中山大学 [1,2,4]三唑并[4,3-b]哒嗪衍生物在制备抗肿瘤药物中的应用
MX2021009371A (es) 2019-02-12 2021-09-10 Sumitomo Pharma Oncology Inc Formulaciones que comprenden inhibidores de proteina cinasa heterociclicos.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2153902A1 (de) * 1971-10-29 1973-05-03 Boehringer Mannheim Gmbh Antimikrobiell wirksame nitrofuranderivate und verfahren zur herstellung derselben
DE2261693A1 (de) 1972-04-01 1974-06-20 Boehringer Mannheim Gmbh Nitroimidazolyl-triazolo-pyridazine und verfahren zu ihrer herstellung
DE2261735A1 (de) 1972-04-01 1974-06-20 Boehringer Mannheim Gmbh Nitroimidazolyl-triazolo-pyridazine und verfahren zu ihrer herstellung
PL91799B1 (de) * 1972-04-01 1977-03-31
DE2254783A1 (de) 1972-04-01 1974-05-16 Boehringer Mannheim Gmbh Nitroimidazolyl-triazolo-pyridazine und verfahren zu ihrer herstellung
DE2215999B2 (de) 1972-04-01 1977-10-20 Boehnnger Mannheim GmbH, 6800 Mannheim 3-(5-nitro-2-imidazolyl)-s-triazolo eckige klammer auf 4,3-b eckige klammer zu pyridazine, verfahren zu ihrer herstellung und arzneimittel
DE2418435A1 (de) * 1974-04-17 1975-10-30 Boehringer Mannheim Gmbh Nitroimidazolyl-triazolo-pyridazine und verfahren zu ihrer herstellung
FR2668151A1 (fr) * 1990-10-23 1992-04-24 Rhone Poulenc Agrochimie Composes a groupe triazolopyridazine leurs preparations et compositions herbicides les contenant.
EA002436B1 (ru) 1996-07-25 2002-04-25 Мерк Шарп Энд Домэ Лимитед Замещенные производные триазоло-пиридазина в качестве лигандов рецепторов гамк
GB9813576D0 (en) * 1998-06-24 1998-08-19 Merck Sharp & Dohme Therapeutic agents
GB9828640D0 (en) 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
DE10038019A1 (de) 2000-08-04 2002-02-14 Bayer Ag Substituierte Triazolopyrid(az)ine
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
AU2002251266A1 (en) * 2001-04-10 2002-10-28 Merck Sharp And Dohme Limited Inhibitors of akt activity
JP4385620B2 (ja) * 2002-03-01 2009-12-16 アステラス製薬株式会社 含窒素複素環化合物
KR20040087335A (ko) * 2002-03-01 2004-10-13 야마노우치세이야쿠 가부시키가이샤 질소 함유 복소환 화합물

Also Published As

Publication number Publication date
US7268136B2 (en) 2007-09-11
AU2003297161B2 (en) 2011-03-10
CA2510534A1 (en) 2004-07-15
EP1575959B1 (de) 2010-07-14
EP1575959A2 (de) 2005-09-21
US20040192696A1 (en) 2004-09-30
MXPA05006478A (es) 2005-09-08
NO20053470L (no) 2005-09-02
ATE473980T1 (de) 2010-07-15
WO2004058769A3 (en) 2004-09-30
CN1742012A (zh) 2006-03-01
RU2005122484A (ru) 2006-01-20
KR101075812B1 (ko) 2011-10-25
KR20050084428A (ko) 2005-08-26
NZ541151A (en) 2008-09-26
WO2004058769A2 (en) 2004-07-15
JP4817661B2 (ja) 2011-11-16
HK1087700A1 (en) 2006-10-20
AU2003297161B8 (en) 2011-03-31
AU2003297161A1 (en) 2004-07-22
CN100567296C (zh) 2009-12-09
JP2006513208A (ja) 2006-04-20
CA2510534C (en) 2011-09-20

Similar Documents

Publication Publication Date Title
DE60333387D1 (de) Triazolopyridazine als proteinkinase-inhibitoren
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
ATE425160T1 (de) Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE540948T1 (de) Pyrrolopyridine als proteinkinasehemmer
DE60330895D1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
DE60214198D1 (de) Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
ATE493401T1 (de) Als proteinkinaseinhibitoren geeignete diaminotriazolverbindungen
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
BRPI0418112A (pt) inibidores de p-38 quinase bicìclico heterocìclicos
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
NO20085373L (no) P38 inhibitorer, deres fremstilling og anvendelse
MXPA06011327A (es) Azaindoles utiles como inhibidores de jak y otras proteinas cinasas.
ATE536353T1 (de) 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
ATE389651T1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen